Microvision Signs Clinical Partner

Medical Center Will Test Retinal Scanning Display Technology as Advanced

Visualization Tool in Cardiology, Cancer Treatment and Anesthesiology



Apr 02, 2001, 01:00 ET from Microvision Inc.

    BOTHELL, Wash., April 2 /PRNewswire/ -- Microvision Inc. (Nasdaq:   MVIS),
 today announced it has entered into a research agreement with the Mayo Clinic
 Rochester to evaluate Nomad(TM), Microvision's retinal scanning display (RSD)
 system, for medical applications in cardiology, cancer treatment and
 anesthesiology. Financial details were not released.
     Nomad's capability for viewing images overlaid onto the patient will be
 tested to determine if augmented vision capability would aid the surgeon and
 attendants who require an enhanced "inside the body" view during such
 procedures as catheter stent placement, radiation treatment of prostate
 tumors, brain surgery and anesthesiology monitoring.
     The agreement with the Minnesota-based clinic is the latest agreement
 Microvision has forged with leading North American medical research and
 surgical centers. Microvision's revolutionary display technology "paints" rows
 of pixels directly onto the user's retina, giving physicians access to
 important data without having to remove their eyes from the patient.  The
 Nomad 'see-through' capability has also been tested and demonstrated for
 medical applications at The Wallace-Kettering Neuroscience Institute (Dayton,
 OH) and the Baylor College of Medicine (Waco, TX) and is currently being
 tested at the Cleveland Clinic Foundation's Minimally Invasive Surgery Center.
     "The wonderful promise of successfully integrating Nomad into operating
 rooms is that it could enable physicians to keep their eyes on their patient
 during the entire procedure," stated Rick Rutkowski, president and CEO.  "It
 could have a revolutionary effect on many procedures, including more
 successful outcomes, less risk to the patient and a possible reduction in
 health care costs.  The unmatched resolution and clarity of the display, along
 with the capability to see overlaid images while keeping eyes on the
 procedure, makes Nomad adaptable to the needs of physicians during demanding
 medical procedures."
 
     About Nomad:
     A unique and innovative way to display images and information,
 Microvision's RSD technology uses an extremely safe low-power beam of light to
 "paint" rows of pixels directly onto the eye, creating a high-resolution,
 full-motion image without the use of electronic screens of any kind.  To the
 viewer, the image appears to be floating directly in front of them at about an
 arm's length away, as if on a large transparent computer screen or television.
 Nomad is Microvision's first commercial product, scheduled for release in
 September 2001.  The product name, which emphasizes portability and mobility,
 will brand Microvision's first offering in successive generations of wearable
 display products.  Microvision has initiated pre-selling Nomad to
 organizations within medical, aviation maintenance and industrial fields that
 require a portable and bright "see-through" display.  Nomad delivers an image
 at least 10 times brighter than competing head-worn display technologies.
 
     About Microvision: www.mvis.com
     Headquartered in Bothell, Wash., Microvision Inc. is the developer of the
 patented retinal scanning display technology and a world leader in micro
 miniature optical scanning technology for display and imaging applications.
 The company's technology has applications in a broad range of military,
 medical, industrial, professional and consumer information products.
 
     Forward-Looking Statement
     The information set forth in this release includes "forward-looking
 statements" within the meaning of Section 21E of the Securities Exchange Act
 of 1934, as amended, and is subject to the safe harbor created by those
 sections. Certain factors that realistically could cause results to differ
 materially from those projected in the company's forward-looking statements
 are set forth in the company's Annual Report on Form 10-K and Quarterly
 Reports on Form 10-Q, as filed with the Securities and Exchange Commission.
 
 

SOURCE Microvision Inc.
    BOTHELL, Wash., April 2 /PRNewswire/ -- Microvision Inc. (Nasdaq:   MVIS),
 today announced it has entered into a research agreement with the Mayo Clinic
 Rochester to evaluate Nomad(TM), Microvision's retinal scanning display (RSD)
 system, for medical applications in cardiology, cancer treatment and
 anesthesiology. Financial details were not released.
     Nomad's capability for viewing images overlaid onto the patient will be
 tested to determine if augmented vision capability would aid the surgeon and
 attendants who require an enhanced "inside the body" view during such
 procedures as catheter stent placement, radiation treatment of prostate
 tumors, brain surgery and anesthesiology monitoring.
     The agreement with the Minnesota-based clinic is the latest agreement
 Microvision has forged with leading North American medical research and
 surgical centers. Microvision's revolutionary display technology "paints" rows
 of pixels directly onto the user's retina, giving physicians access to
 important data without having to remove their eyes from the patient.  The
 Nomad 'see-through' capability has also been tested and demonstrated for
 medical applications at The Wallace-Kettering Neuroscience Institute (Dayton,
 OH) and the Baylor College of Medicine (Waco, TX) and is currently being
 tested at the Cleveland Clinic Foundation's Minimally Invasive Surgery Center.
     "The wonderful promise of successfully integrating Nomad into operating
 rooms is that it could enable physicians to keep their eyes on their patient
 during the entire procedure," stated Rick Rutkowski, president and CEO.  "It
 could have a revolutionary effect on many procedures, including more
 successful outcomes, less risk to the patient and a possible reduction in
 health care costs.  The unmatched resolution and clarity of the display, along
 with the capability to see overlaid images while keeping eyes on the
 procedure, makes Nomad adaptable to the needs of physicians during demanding
 medical procedures."
 
     About Nomad:
     A unique and innovative way to display images and information,
 Microvision's RSD technology uses an extremely safe low-power beam of light to
 "paint" rows of pixels directly onto the eye, creating a high-resolution,
 full-motion image without the use of electronic screens of any kind.  To the
 viewer, the image appears to be floating directly in front of them at about an
 arm's length away, as if on a large transparent computer screen or television.
 Nomad is Microvision's first commercial product, scheduled for release in
 September 2001.  The product name, which emphasizes portability and mobility,
 will brand Microvision's first offering in successive generations of wearable
 display products.  Microvision has initiated pre-selling Nomad to
 organizations within medical, aviation maintenance and industrial fields that
 require a portable and bright "see-through" display.  Nomad delivers an image
 at least 10 times brighter than competing head-worn display technologies.
 
     About Microvision: www.mvis.com
     Headquartered in Bothell, Wash., Microvision Inc. is the developer of the
 patented retinal scanning display technology and a world leader in micro
 miniature optical scanning technology for display and imaging applications.
 The company's technology has applications in a broad range of military,
 medical, industrial, professional and consumer information products.
 
     Forward-Looking Statement
     The information set forth in this release includes "forward-looking
 statements" within the meaning of Section 21E of the Securities Exchange Act
 of 1934, as amended, and is subject to the safe harbor created by those
 sections. Certain factors that realistically could cause results to differ
 materially from those projected in the company's forward-looking statements
 are set forth in the company's Annual Report on Form 10-K and Quarterly
 Reports on Form 10-Q, as filed with the Securities and Exchange Commission.
 
 SOURCE  Microvision Inc.